PMID- 33013641 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201006 IS - 1664-2295 (Print) IS - 1664-2295 (Electronic) IS - 1664-2295 (Linking) VI - 11 DP - 2020 TI - IV/IT hUC-MSCs Infusion in RRMS and NMO: A 10-Year Follow-Up Study. PG - 967 LID - 10.3389/fneur.2020.00967 [doi] LID - 967 AB - Background: Stem cell transplantation is emerging as a potential therapeutic strategy in several autoimmune diseases. However, the safety and feasibility of long-term combined intravenous (IV) and intrathecal (IT) administration of hUC-MSCs in relapse remitting multiple sclerosis (RRMS) and neuromyelitis optica (NMO) is largely unknown. Objectives: In this study, we followed up the long-term safety and feasibility of combined IV and IT human umbilical cord mesenchymal stem cells (hUC-MSCs) transplantation in patients with RRMS and NMO. Methods: Five NMO patients and 5 RRMS patients were treated intravenously (4 times) and intrathecally (3 times) over a 21-day period with low-dose allogeneic umbilical cord blood-derived MSCs. All of the patients were monitored regularly by an investigator in a blinded manner to access the Expanded Disability Status Scale, MRI characteristics, and adverse events every 3 months within 12 months and once every year thereafter for 10 years after transplantation. Results: During the long-term follow-up, our data suggested that combined IV and IT administration of hUC-MSCs transplantation is safe and feasible. None of the intolerant adverse events, such as tumor formation and peripheral organ/tissue disorders, were observed throughout the 10-year follow-up. Conclusions: These data suggest that combined intravenous and intrathecal low-dose hUC-MSCs transplantation is safe and feasible in RRMS and NMO patients in the long term. The conclusion requires confirmation by future clinical trials in a larger cohort. CI - Copyright (c) 2020 Lu, Zhu, Liu, Wu, Xu and Zhang. FAU - Lu, Zhengjuan AU - Lu Z AD - Department of Neurology of Nanjing Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China. AD - Department of Neurology, Institute of Brain Sciences, Nanjing University, Nanjing, China. AD - Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing, China. AD - Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China. AD - Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China. FAU - Zhu, Lin AU - Zhu L AD - Department of Neurology of Nanjing Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China. AD - Department of Neurology, Institute of Brain Sciences, Nanjing University, Nanjing, China. AD - Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing, China. AD - Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China. AD - Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China. FAU - Liu, Zhuo AU - Liu Z AD - Department of Neurology of Nanjing Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China. AD - Department of Neurology, Institute of Brain Sciences, Nanjing University, Nanjing, China. AD - Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing, China. AD - Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China. AD - Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China. FAU - Wu, Jiayong AU - Wu J AD - Department of Neurology of Nanjing Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China. AD - Department of Neurology, Institute of Brain Sciences, Nanjing University, Nanjing, China. AD - Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing, China. AD - Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China. AD - Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China. FAU - Xu, Yun AU - Xu Y AD - Department of Neurology of Nanjing Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China. AD - Department of Neurology, Institute of Brain Sciences, Nanjing University, Nanjing, China. AD - Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing, China. AD - Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China. AD - Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China. FAU - Zhang, Cun-Jin AU - Zhang CJ AD - Department of Neurology of Nanjing Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China. AD - Department of Neurology, Institute of Brain Sciences, Nanjing University, Nanjing, China. AD - Jiangsu Key Laboratory for Molecular Medicine, Medical School of Nanjing University, Nanjing, China. AD - Jiangsu Province Stroke Center for Diagnosis and Therapy, Nanjing, China. AD - Nanjing Neuropsychiatry Clinic Medical Center, Nanjing, China. LA - eng PT - Journal Article DEP - 20200908 PL - Switzerland TA - Front Neurol JT - Frontiers in neurology JID - 101546899 PMC - PMC7506071 OTO - NOTNLM OT - human umbilical cord-derived mesenchymal stem cells OT - long-term follow-up OT - neuromyelitis optica OT - relapse remitting multiple sclerosis OT - safety EDAT- 2020/10/06 06:00 MHDA- 2020/10/06 06:01 PMCR- 2020/09/08 CRDT- 2020/10/05 06:15 PHST- 2019/10/16 00:00 [received] PHST- 2020/07/24 00:00 [accepted] PHST- 2020/10/05 06:15 [entrez] PHST- 2020/10/06 06:00 [pubmed] PHST- 2020/10/06 06:01 [medline] PHST- 2020/09/08 00:00 [pmc-release] AID - 10.3389/fneur.2020.00967 [doi] PST - epublish SO - Front Neurol. 2020 Sep 8;11:967. doi: 10.3389/fneur.2020.00967. eCollection 2020.